lifestyle.thedishh.com

Author: DBV Technologies S.A.

DBV Technologies to Participate in Upcoming March Investor Conferences

March 4, 2026
Information Regarding the Total Number of Voting Rights and Total Number of Shares of the Company as of February 28, 2026

March 3, 2026
DBV Technologies Highlights Additional Data from Successful Phase 3 VITESSE Study at the AAAAI 2026 Annual Meeting

February 28, 2026
DBV Technologies to Present Additional Data from the VITESSE Phase 3 Study of the VIASKIN® Peanut Patch in Children Ages 4-7 Years and Discuss Future of EPIT in the Treatment Landscape at AAAAI 2026 Annual Meeting

February 10, 2026
DBV Technologies to Participate in the Guggenheim Securities Emerging Outlook: Biotech Summit

February 9, 2026
Information Regarding the Total Number of Voting Rights and Total Number of Shares of the Company as of January 31, 2026

February 7, 2026
DBV Technologies annonce avoir reçu un produit brut de 166,7 millions d’euros suite à l’exercice intégral des Bons de Souscription (BS) issus des ABSAs et des BS issus des PFW-BS-PFW émis dans le cadre de son financement de mars 2025

January 20, 2026
DBV Technologies annonce avoir reçu un produit brut de 166,7 millions d’euros suite à l’exercice intégral des Bons de Souscription (BS) issus des ABSAs et des BS issus des PFW-BS-PFW émis dans le cadre de son financement de mars 2025

January 20, 2026